BOOK 2019
SUCCESS STORIES

Réseau SATT
Les Sociétés d'Accélération du Transfert de Technologies

INVESTIR L'AVENIR

BOOK 2019
SUCCESS STORIES

Réseau SATT
Les Sociétés d'Accélération
du Transfert de Technologies

Contents

Editorial

This Book of Success Stories 2019 brings together specific cases that illustrate the work done by the Technology Transfer Accelerator Offices (SATTs). Deep Tech Start-ups founded, innovative technologies licensed and projects under development - all examples that demonstrate the work carried out by our teams. Researchers and industrial partners have kindly given us an account of their successful collaborations as first beneficiaries of the SATTs work.

To date, 900 operating license agreements have been signed, enhancing the national economic fabric and strengthening the competitiveness of businesses as well as the 420 start-ups founded and supported by the SATTs. Through its organisation and effectiveness, the SATT network is now more than ever ready to respond to economic and societal challenges by optimizing the value of research and innovation.

Philippe Nerin
President SATT Network
President SATT AxLR

The SATTs

The Technology Transfer Accelerator Offices, SATTS, are simplified joint stock companies created by a number of public research institutions within the framework of the Investment for the Future programme (PIA) and value optimization activities.

€856M were allocated for the creation of the SATTs, much of which is devoted to the creation of intellectual property assets and investment in maturation.

With a unique fund in France, the SATTs have access to expertise and inventions developed by public researchers in their area. They mobilize dedicated professional teams to support the inventions up to the point of transfer to a company:

- Identification of high added value innovative projects and investment in technological maturation for preparation for marketing;
- Protection of research results by filing intellectual and industrial property rights and keeping them in force.
- Commercialization by licensing technologies and creating innovative business opportunities.
- Creation of Deep Tech Start-ups

MAJOR GROUPS PLACE THEIR TRUST IN SATTS

BASF relies on the SATT Network for identification of innovative biocontrol technologies.

The BASF Group opted to rely on SATT Network expertise to set up a technological scouting operation. The partnership seeks to identify innovative biocontrol technologies originating in public research.

Decathlon is marketing a new generation of mouthguard, an innovation emanating from Bordeaux-based public research.

A new intraoral protection system supported by Aquitaine Science Transfert is today being marketed by the French group, Decathlon, offering athletes greater comfort and safety.

Pierre Fabre: marketing of a valuable demo-cosmetic active ingredient: Acefylline, identified thanks to research work carried out by a Toulouse laboratory.

Toulouse Tech Transfer has signed an operating agreement with the Pierre Fabre group for commercialization via its Ictyane Hydra range by Laboratoires Dermatologiques Ducray, a valuable demo-cosmetic active ingredient: Acefylline.

The SATT Network

The SATT Network association was set up in 2014, to carry out shared activities aimed at increasing the efficiency, transparency and visibility of the SATTs.

Through its work, the SATT Network:

- Makes available a common catalogue of technologies ready to be transferred;
- Develops partnerships;
- Displays shared values;
- Organizes joint communication.

Office

President
Philippe Nerin
President
SATT AxLR

Secretary
Céline Clausener
Director of Public Affairs
SATT Erganeo

Treasurer
Vincent Lamande
President
SATT Ouest Valorisation

SCOPE



In total

148,659 Researchers & PhD Students

163 Establishments

ACHIEVEMENTS

The SATT Network has signed two memoranda of understanding with Chinese innovators: OuiCrea, the Bay Valley Innovation Center of the National Eastern Tech-Transfer Center (NETC) and Shanghai University of Science and Technology.

Institutional representation work has been undertaken by the SATT Network bureau and its members with ministerial and local public decision-makers, partners of the innovation ecosystem.

The SATT Network is frequently sought by foreign delegations visiting France that are interested in the SATT model: for example, in 2019, Colombia, Brazil and Russia, among others.

Written contributions have been produced by the SATT Network as part of various national consultations (multi-annual research programming act (LPPR), Productive Pact, etc.).

The SATTs' shared participation in eight events was coordinated by the SATT Network: France Tech Transfer Invest (FTTI), Innovatives SHS, Vivatechnology, Forum 1er contact, Rendez-vous Carnot, PhDTalent Career Fair, BioFIT, Journée ANR.

Over 750 protected innovations emanating from SATT portfolios are now available in an online catalogue of technological offerings on the SATT Network website: www.satt.fr.

WORK GROUPS

Business Development: in order to facilitate the open innovation approach of Large Groups and intermediate-sized enterprises (ISE), the SATT Network launched a customized technological scouting proposal, incorporating the entire SATT technology offering. A number of operations have already been undertaken, notably, with BASF and Spie Batignolles.

Start-up: the work group discusses SATT practices, including the production of common documents, collective events through the sharing of a file covering all Network start-ups, calls for projects in progress and links with investment funds.

International: in 2019, the SATT Network deployed its promotion activities at European level, incorporating the National Association Advisory Committee (NAAC) within the European association ASTP. In this regard, it is involved in a project to link up European Technology Transfer Offices (TTO).

BPIFRANCE, SATT OPERATOR

In 2019, Bpifrance became the new operator of work to "integrate the SATTs, incubators and accelerators" under the Investments for the Future programme (PIA), replacing in this role, the Caisse des Dépôts et Consignations (CDC), which had been the SATTs' operator since their creation in 2012.

The SATT Network thanks the CDC for its work and support over these six years, during which many challenges were faced and successes achieved. The SATT Network is now working actively with Bpifrance to boost the emergence of start-ups and tomorrow's Deep Tech Technologies. Actions such as the French Tech Seed Fund or Deep Tech Tour are illustrations of this daily work.

Results

11,554
Innovative projects detected and analysed

2,629
Priority patent applications filed

594
Specialist professionals

418
Start-ups created

899
License agreements signed with companies

€494 M
in funds raised by SATT start-ups

1,428
jobs created by SATT start-ups

Aggregate figures as at 01/07/2019

Start-ups

TreeFrog Therapeutics

Founded: December 2018
CEO: Kévin Alessandri

Winner of the Grand Prize in the i-Lab 2018 competition, TreeFrog has developed a disruptive innovation for the mass production of cell therapies based on 3D stem cell culture. Originating in Bordeaux University, the National Centre of Scientific Research (NCSR) and the IOGS, TreeFrog aims to make the cost of cell therapies a hundred times cheaper, in order to treat the millions of patients suffering from chronic or degenerative diseases.

License agreements signed

TreeFrog signed a license agreement with Aquitaine Science Transfert in March 2019, with the objective of industrializing the technology and producing the first batches of clinical quality in 2021.

News

In April 2019, TreeFrog delivered a first batch of 143M stem cells to the Institut Imagine. In May, the company raised over €7 M, in addition to €3 M in French and European funding.

Fundraising: €7.1 M

Number of jobs: 18 employees

Maturation programme: yes

Further information: treefrog.fr

WOMED

Womed

Founded: March 2018
CEO: Gonzague Issenmann

Womed addresses the main mechanical cause of infertility in women: intra-uterine adhesions. This is an adhesion of the uterus walls due to poor healing after surgery such as curettage or fibroma removal. They are the cause of miscarriage in one out of every five cases. Womed Leaf, Womed's product, makes it possible to eliminate these adhesions.

License agreements signed

Granting of an exclusive global license agreement to Womed for the use of patents originating in work by the Artificial Biopolymers Department of the Institut des Biomolécules Max Mousseron and the Obstetrics and Gynaecology department of CHU Nîmes (University Hospital).

News

The company is in the process of carrying out all the preclinical tests with a view to starting the first clinical study by 2020, and obtaining its EC Marking.

Fundraising: €1.1 M

Number of jobs: 4 employees

Maturation programme: yes

Further information: axlrprojets.com/antisyn

aXLR SATT

QFLUIDICS

Qfluidics

Founded: May 2019
CEO: Vincent Marichez

Qfluidics' purpose is:

- The synthesis and sale of ferrofluids;
- The development, manufacture and sale of solutions and services for professionals relating to ferrofluids (pumps, valves, art, etc.).

© Qfluidics

License agreements signed
Exclusive license agreement all domains and worldwide for patent No. EP17305070 "Device and method for circulating liquids" and for know-how (SOLEAU envelope No. DSO2018012587 filed on 17/10/2018).

News
Qfluidics is in the process of finalizing its prototype liquid tube, low-shear pumping system. It is in discussion with major manufacturers concerning a collaborative project aimed at producing a perfectly adapted final product.

Fundraising: €120 K

Number of jobs: 2 employees

Maturation programme: yes

Further information: www.qfluidics.com

CONECTUS
FOURNISSEUR OFFICIEL D'INNOVATIONS

ermium THERAPEUTICS

Ermium Therapeutics

Founded: June 2019
CEO: Joël Crouzet



Ermium Therapeutics is a biotechnology company involved in the development of innovative health products for autoimmune and inflammatory diseases. Founded by researcher Jean-Philippe Herbeuval, Kurma Partners, Domain Therapeutics and Erganeo, the start-up is developing a new class of drug candidates that will be capable of controlling autoimmune diseases.

Licencs agreements signed

The start-up is based in Paris and has signed a worldwide exclusive license agreement on intellectual property from the National Centre of Scientific Research (NCSR) and Paris Descartes University (France) within the context of an agreement with Erganeo.

News

Ermium Therapeutics recently won the i-Lab 2019 innovation award from the Ministry for Research and Further Education.

Fundraising: €6.3 M

Number of jobs: 2 employees

Maturation programme: yes

Further information: ermium.com

ERGANEO
L'AVENIR EST FAIT D'AUDACE

Microlight3D

Founded: 2016
CEO: Denis Barbier



Microlight3D is a manufacturer of ultra-high resolution 2D and 3D micro-printing systems. By combining 2D and 3D micro-printing techniques, Microlight3D is able to offer its customers greater flexibility for the creation of complex, larger format pieces. The company intends to supply systems making faster and more complex micro-printing possible for tomorrow's applications.

License agreements signed

Four intellectual property assets (patent, software, know-how) have been granted to Microlight 3D under license by Linksium. These IP assets stem from the maturation of the 3D PRINTER project with Liphy laboratory, whose supervisory bodies are Grenoble Alpes University (UGA) (validation company) and the CNRS.

News

European funding through participation in the nAngioDerm project, which develops solutions for acute wounds and chronic ulcers that do not heal.

Fundraising: in the process of preparation

Number of jobs: 9 employees

Maturation programme: Yes

Further information: www.microlight.fr

NEUROCORT
TECHNOLOGIES

Neurocort Technologies

Founded: June 2019
CEO: Jean-Noël Bremond

Originating in the LTSI laboratory for processing and information systems, laboratory of Rennes 1 University and Inserm, the Neurocort Technologies start-up, founded in 2019, addresses cognitive impairment problems using high-resolution electroencephalography (HR-EEG). Neurocort's mission is to industrialize, promote and sell a generation of innovative medical equipment designed for the diagnosis of cerebral pathologies, particularly, the early diagnosis of neurodegenerative diseases.
This project was funded with support from the European Regional Development Fund (ERDF) for the Brittany Region.

License agreements signed
One software license, four patent licences and a trademark license.

News
Fundraising planned for 2020.

Fundraising: pending

Number of jobs: 4 employees

Maturation programme: yes

Find out more : www.neurocort.com

OUEST VALORISATION
Ressources d'innovation

GAOMA Therapeutics

Founded: February 2019
CEO: Jordan Guyon

GAOMA is developing innovative therapeutic lipid molecules for the treatment of epilepsy. These molecules are based on new active principles, coupled with vectors that make it possible to provide certain pharmacokinetic properties of interest. Given the mechanism of action of these molecules, GAOMA aims to rapidly explore their potential activity in other areas.

License agreements signed

One license signed on 18 June 2019, with one patent.

News

GAOMA is working on its first fundraising, which, among other things, will enable the company to launch the preclinical development of its lead programme.

Fundraising: pending

Number of jobs: 6 employees

Maturation programme: yes

Find out more : www.gaoma-tx.com

basecamp vascular

BaseCamp Vascular

Founded: April 2016
CEO: Raphaël Blanc

BaseCamp Vascular is developing an endovascular navigation system for doctors treating stroke patients. These innovative medical devices can be activated and facilitate progression towards the target area, resulting in faster, safer and more effective interventions. In future versions, these active catheters will be used for other applications such as cardiology or vascular surgery.

License agreements signed

The filing of a patent in 2010, for the technology developed at the ISIR and a maturation programme led to the signing of a license agreement between SATT Lutech and BaseCamp Vascular.

News

BaseCamp Vascular progressed towards the industrialization of intelligent catheters on the technical, reglamentary (ISO certification) and financial fronts through major fundraising in 2018.

Fundraising: €3 M

Number of jobs: 10 employees

Maturation programme: yes

Further information: www.sattlutech.com/2017/08/31/catheter-actif-icath/

SATT LUTECH

ZYMOPTIQ
Understanding Enzymes

Zymoptiq

Founded: 2019
CEO: Philippe Pebay



Zymoptiq offers enzymatic sensor analytical technology for measuring enzymatic activity. It can be used for all types of enzymatic measurement (R&D screening, quality control, etc.) and transforms the possibilities for the characterization and improvement of products and procedures in all fields in which enzymes are used (animal nutrition, agrifood, biofuel, cosmetics, detergents, purification, biomedical, etc.).

License agreements signed

The license agreement concerns the exploitation of Reflex technology developed by IEMN researchers. SATT Nord financed and supported the researchers during technological maturation, enabling the filing of two patents.

News

Zymoptiq offers its first commercial property for measuring the activity of xylanase. Other products are under development (amylase, glucanase, protease, etc.).

Fundraising: pending

Number of jobs: 7 employees

Maturation programme: yes

Further information: zymoptiq.com

SATT NORD

Exotrail

Founded: August 2017
CEO: David Henri



Space industry start-up, Exotrial, is developing electric operation and propulsion solutions for the small satellite market. The miniature Hall Effect thrusters it has developed enable its customers' satellites to change orbit after launching. The performance and service-life of small satellite constellations are therefore significantly improved.

License agreements signed

An exclusive worldwide license agreement was signed with Exotrail in July 2018, for the use of the technology originating from Versailles St Quentin University, the CNRS, the Ecole polytechnique and Synchrotron Soleil.

News

NanoAvionics and Exotrail partnered to integrate Exotrail's propulsion system into its M6P nanosatellite bus, which is scheduled to be launched by the beginning of 2020 on a PSLV rocket.

Fundraising: €6 M

Number of jobs: 22 employees

Maturation programme: yes

Further information: exotrail.com

YUKIN Therapeutic

Yukin Therapeutics

Founded: June 2018
Managing Director: Arnaud Foussat

Yukin Therapeutics is a biotech company founded by Advent France Biotechnology and SATT Sud-Est. It is working on the development of new therapeutic molecules targeting protein NIK, which is involved in the development of a number of cancers. Yukin Therapeutics has POC in animal models and aims to identify a first drug candidate in order to launch a clinical trial in oncology.

License agreements signed

License for two patents in co-ownership. Univ. Nice Sophia Antipolis, Inserm, CNRS, CHU Nice. The invention, co-funded with Canceropôle PACA, concerns a therapeutic arsenal targeting solid cancers.

News

In December 2018, SATT Sud-Est took a stake in the start-up. On June 4, 2019, Yukin Therapeutics announced fundraising of €3.3 M for the development of new cancer treatments.

Fundraising: €3.3 M

Number of jobs: 5 employees

Maturation programme: yes

Further information: www.adventfb.com/#portfolio

SATT SUD-EST
ACCELERATING TECHNOLOGY TRANSFER

SINTERmat

Founded: October 2016
CEO: Foad Naimi

SINTERmat operates in the area of powder metallurgy, supported by major expertise in rapid sintering technology. This patented technology makes possible the sintering of powders of different natures to produce dense pieces with controlled micro-structures. SINTERmat provides innovative solutions to manufacturers in sectors including metallurgy, defence, luxury, energy, aeronautical, etc.

License agreements signed
At the end of 2018, SINTERmat and SAYENS entered into a license agreement for patented rapid Spark Plasma Sintering technology originating in the ICB laboratory (UMR 6303 CNRS / University of Burgundy).

News
Winner of the #LetsgoFrance 2019 prize. Installation in June 2019, in new premises in Montbard (Côte-d'Or) and setting up of a unique production unit in Europe.

Fundraising: €1.5 M

Number of jobs: 10 employees

Maturation programme: yes

Further information: www.sinter-mat.com

POWER DESIGN TECHNOLOGIES

Power Design Technologies

Founded: August 2016
CEO: Nicolas Videau


© Power Design Technologies

Power Design Technologies opens up a new era in the design of electrical energy converters with PowerForge:
The first software tool for the design of converters based on “multi-level” technology. This major technology offers a factor-two gain in terms of mass, volume and consumption compared with conventional solutions.

License agreements signed

Granting of a worldwide patent + software license agreement, with participation by TTT and the establishment the inventions originated from, Toulouse INP, in the company’s stock.

News

A new version of the software. Three new recruits for sales & marketing functions in order to accelerate the business, particularly internationally. Signing of partnership agreements with key players.

Fundraising: €600 K

Number of jobs: 12 employees

Maturation programme: yes

Find out more : www.powerdesign.tech

TOULOUSE TECH TRANSFER

Licensed Projects

TEMRI

The real-time display system for MRI-guided thermotherapies. The technology will improve patient treatment using minimally invasive therapies.



Goal of the technology

The development of pioneering solutions for thermotherapies enabling practitioners to view the effects of their MRI procedures in real time and predict therapeutic effects in the clinical fields of cardiology, oncology or neurology; to provide better solutions that are significantly more effective and safer than current standards of care.

Goal of the partnership

The signing of the exclusive license agreement will make it possible to develop and market the solution. The TEMRI project received €258 K in support during maturation from SATT Aquitaine and led to the creation of the company, CERTIS THERAPEUTICS, awarded the i-Lab 2019 grand prize.

Laboratory: Centre for cardio-thoracic research, Bordeaux CRCTB (Bordeaux University, Inserm, IHU Liryc)

Company: CERTIS Therapeutics

CERTIS THERAPEUTICS

AQUITAINE SCIENCE TRANSFERT
Accélérateur d'innovations

Synthesis of complex amphiphilic molecules

The purpose of this project is the optimization of the synthesis of amphiphilic polymers in accordance with company production constraints.



Goal of the technology

Through this collaboration, Anatrace, an internationally recognised leader in the production of reagents for the study of membrane proteins, is adding a new listing to its catalogue in a market always on the lookout for new molecules.
These non-ionic, amphiphilic polymers are capable of extracting and stabilising membrane proteins without denaturing them and without the use of detergent molecules.

Goal of the partnership

Thanks to this transatlantic agreement, SATT AxLR will benefit from royalties from the sale of these amphiphilic polymers.

Laboratory: University Team of Bio-organic Chemistry and Amphiphilic Systems of the IBMM (Institut des Biomolécules Max Mousseron - Montpellier)

Company: Anatrace

anatrace

SATT AxLR

STRAS

Remote-control robotic prototype to assist flexible endoscopic surgery.

Goal of the technology

Development of a flexible endoscopic robot compatible with clinical tests that must be approved by the ANSM and the CPP. STRAS enables a surgeon without prior experience in endoluminal surgery to perform complete surgical tasks alone and safely. The dissection speed is also improved compared with manual instruments, even when used by experts.

Goal of the partnership

Sterilization of the system, re-development of the software in order to obtain certification for clinical use, and analysis of the risks due to clinical use of the robot. Usability tests by endoscopic and other surgeons to compare it to conventional medical equipment.

Laboratory: Laboratoire ICube, UMR 7357 (Strasbourg University, CNRS, INSA, ENGEES), AVR (Automatic Vision and Robotics) team.

Company: Karl Storz

High output production of extracellular vesicles (EVs)

The innovative extracellular vesicle (EV) production procedure consists of stimulating cells to induce a massive production of EVs through generation of a controlled turbulent flow.



Goal of the technology

EVerZom's mission is to facilitate and speed up the emergence of new therapeutic strategies in regenerative medicine. Our new "custom" EV production and engineering platform will finally make it possible to provide new industrial production solutions to meet the needs of academics and manufacturers devising tomorrow's biotherapies.

Goal of the partnership

The goal of the partnership is to optimize the value of the innovations developed and patented at the Laboratoire Matière et Systèmes Complexes. EverZom was created to adapt and develop these technologies in order to meet the needs of a fast-emerging market.

Laboratory: Laboratoire Matière et Systèmes Complexes de l'Université Paris Diderot

Company: EVerZom

EVerZom

ERGANEO
L'AVENIR EST FAIT D'AUDACE

PUMAG

Compact current (cm^3) high intensity (5kA) system for generating a pulsed magnetic field of up to 10T.

Goal of the technology

The compact nature and there being no need for cryogenic fluid means that these sources of magnetic field are easy to install and use in laboratory equipment (meteorology) or integrate into a microscope stage (biology). Magnetic field intensities 10 to 1,000 times greater than those produced by sources of magnetic fields of comparable size are achievable.

Goal of the partnership

HPROBE is a company whose technological competitive advantage is based on two patents filed by the CNRS. Two exclusive worldwide license agreements have been signed between HPROBE and the CNRS via LINKSIUM. The first patent emanates from the Magnus maturation project with the Spintec laboratory. The second, has its origins in the Pumag maturation project with the Institut Néel.

Laboratory: Institut Néel and Universidade Federal do Parana (Curitiba, Brazil).

Company: Hprobe

Hprobe

Linksium
technology transfer & startup building
Grenoble Alpes

OphtAI

This system is a new automated mass screening solution for retinal disorders by diagnostic algorithms.

Goal of the technology

At the core of progress in AI and BigData, the work carried out on indexation and research into patient image databases are decisive contributors, assisting diagnosis and decision-making in the detection of retinopathy, and making better treatment possible for almost half a billion people at risk in the world today. A clinical study and medical device labelling currently in progress will consolidate the technology.

Goal of the partnership

"We are a breakthrough innovation: a revolution in screening for retinal disease. Being able to tell our distributors abroad that we were on the CES promotes the value of our technology. We have worked with very good partners - Ouest Valorisation, LaTIM(UBO), AP-HP, ADCIS - so expect to continue working together to develop the solution."

Laboratory: Laboratoire de Traitement de l'Image Médicale (LaTIM) at Bretagne Occidentale University, Brest, and Assistance Publique – Hôpitaux de Paris (AP-HP).

Company: Evolucare

[kosmopoli:t]

The restaurant offering specialities from all over the world, where orders are placed in over 60 different languages!

Goal of the technology

Created by a team of connoisseurs of games and sounds, [kosmopoli:t] is an entertaining phonetic board game in which players: the chef, floor manager or waiter, must serve a maximum number of orders to customers who are speakers of dialects from all over the world. The aim of the game is to bring the wealth of linguistic diversity to the largest number of people possible and combat received ideas about language.

Goal of the partnership

Two years in the making, the partnership between Laboratoire DDL and Jeux OPLA combines flavours and sounds for a unique recreational experience. Its goal is to entertain the ear and the taste-buds by connecting voices of the world through the factor that sets mankind apart from other species: cooking and language.

Laboratory: Dynamiques Du Langage (DDL - Lumière Lyon 2 University, CNRS)

Company: Jeux OPLA

Actronika

High performance, miniature haptic platform that can be integrated into human-machine interface solutions which reproduce numerous realistic tactile sensations.



Goal of the technology

Actronika's goal is to facilitate the integration of haptic technologies into the automotive, mobile, video game and entertainment sectors by offering its customers a platform that favours interactions between users and machines. The technology offers users pleasant and diverse tactile experiences that are adapted for each use and very realistic.

Goal of the partnership

The goal of Actronika's maturation programme being to develop an optimized industry-ready product led to the signing of an exclusive license agreement on the technology patented in 2011. The latter was co-founded by Vincent Hayward, the inventor of the patent.

Laboratory: ISIR (Institut des Systèmes Intelligents et de Robotique) at the Sorbonne University.

Company: Actronika

CD 47

New innovative peptide representing a pharmacological target of interest for the development of therapeutic tools in oncology.



Goal of the technology

This antagonistic peptide inhibits the binding of TSP-1 to its receptor CD47 (peptide TAX2), reducing the vascularization of tumours, inducing an anti-metastatic response and activating an immune response directed against cancerous cells. By financing this project, SATT Nord consolidate and extend the proof of concept for the therapeutic use of this drug candidate.

Goal of the partnership

Within the context of the development of anti-cancer immunotherapy strategies, Apmonia Therapeutics aims to accelerate the reglamentary preclinical and clinical developments of peptide TAX2, while continuing research and development activities to strengthen the company's assets.

Laboratory: UMR CNRS 7369 MEDyC of the University of Reims Champagne-Ardenne

Company: Apmonia Therapeutics

TEMPO

Decision-making tool for financial asset portfolio management.

Goal of the technology

While a number of tools and software solutions have facilitated the management of risks and reporting of derivative portfolios, the question of optimum moments for intervention still appeared to be unresolved. This is all the more critical in the case of complex portfolios. The decision-making tool, TEMPO, meets this need by supplying an automatic and optimized risk management strategy.

Goal of the partnership

The goal of the collaboration, shared by all partners, was to develop a software solution and to evaluate its benefits for Kesitys customers. The goal of the maturation project: to demonstrate the performance and gains obtained by the TEMPO software solution.

Laboratory: CNRS, Ecole polytechnique, Grenoble INP

Company: Kesitys

Generic Transducer

The smallest, selective, gas sensor component in the world; it can make your smartphone capable of identifying a specific gas and measuring its concentration. The best solution for incorporating a gas detection and measuring function in any connected object.

© Nanoz

Goal of the technology

Due to its small size, the sensor can be integrated into smartphones and tablets. It is compatible with microelectronic manufacturing processes and can be mass-manufactured at low cost. With extremely low energy consumption, it offers a very high degree of autonomy, making it the ideal solution for connected objects.

Goal of the partnership

Developments made by the CNRS and Aix-Marseille Université give the technology credibility thanks to the international aura of its co-inventors, which include Prof. Khalifa Aguir. On the basis of this partnership, Nanoz aims to become the gas sensor component market leader with an innovative range based on protected break-through technologies.

Laboratory: Institut Matériaux Microélectronique Nanosciences de Provence (IM2NP UMR 7334 Aix-Marseille Université, CNRS)

Company: Nanoz (Rousset, 13)

NANOZ

SATT SUD-EST
ACCELERATING TECHNOLOGY TRANSFER

SYSARK

The patented technology is a robotic solution that facilitates the automatic handling of radioactive drugs used in departments of nuclear medicine.



Goal of the technology

With the SYSARK robot, the company aims to reduce the risk to handlers and patients of exposure to radioactivity during scans. It also guarantees improved reliability, limiting the risk of error affecting patients during the scan.

Goal of the partnership

A license agreement between SAYENS and the company, SYSARK, allows the latter to develop and market the robotic solution to healthcare establishments in particular. SYSARK aims to become the leader in the robotozation of radioactive drug preparation in Europe. It will rely on a partnership with SAYENS in the field of medical devices.

Laboratory: Laboratoire CRAN – UMR 7039 Lorraine University / CNRS

Company: SYSARK

SYSARK TECHNOLOGIES MEDICALES

SAYENS SATT CATALYSEUR D'INNOVATIONS

EZ-Curve

High precision metrology technology for the manufacture of semi-conductors to significantly improve the control of operations to deposit thin layers of materials.

© TTT

Goal of the technology

EZ-Curve is a major technological innovation compared with existing measuring instruments on the Molecular Beam Epitaxy market. It makes real-time measurement possible in the case of significant production times, curvature and faults on any type of surface. It also offers broader perspectives by contributing to the implementation of automated advanced control processes.

Goal of the partnership

EZ-Curve will enable RIBER to extend its offering of solutions and services by providing research laboratories and manufacturers with means of improving their processes and the results of their developments.
This is the 100th operating license agreement signed by TTT since its creation.

Laboratory: LAAS-CNRS

Company: RIBER

RIBER

TOULOUSE TECH TRANSFER

Maturing projects

POLARGLASS

This is a process to improve the mechanical properties and durability of glass by thermal poling. Originating in the Bordeaux University, the CNRS and Bordeaux INP, the technology makes it possible to obtain a 400nm layer of pure silica on the surface of glass.



Applications

The improvement in its mechanical properties and its durability will reduce losses during production for glaziers, as well as during storage and delivery. The biggest user of flat glass is the building sector and in the case of special glass, pharmaceutical vials and screens.

Type of maturation

€309 K not including HR (feasibility study, market evaluation, industrial prototype, filing of a PCT).

Stage of development

Feasibility of the process - contact not made. Next phase: scale-up in accordance with manufacturers' requirements.

Intellectual property

Initiation of national and regional phases in Europe, USA, Canada, Japan.

SCANORHIZE

The project consists of producing an energy self-sufficient, automated image acquisition device to observe and track the biological functioning of soil. The images obtained are analysed via an artificial intelligence module to extract the relevant activity indicators.

Applications

This innovation opens a window directly in the soil for the observation and study of roots, fungi, mycorrhizae, macrofauna and earth pathogens in real time. This device is intended for research and experimentation in the forestry and agriculture sectors, as well as green areas.

Type of maturation

Standard partnership maturation with the rapid marketing of an initial version.

Stage of development

Prototypes have been tested to date and the solution will be marketed in 2020.

Intellectual property

The technology is protected via the program protection agency.

REMEDy

Rare earth elements (REEs) are used in numerous high-technology products, including permanent magnets. On the boundary between chemistry and physics, this new solvent-free procedure for REE separation reduces the energy required by the usual procedures.



Applications

The procedures extensively used today are polluting, organic solvent-based ones. Here, REEs are separated using mineral concentrate or solutions from recycling processes without solvents.

Type of maturation

The investment will make it possible to target the most suitable application and carry out a pilot study.

Stage of development

First laboratory results with 97% purity of lanthane compared with heavy rare earth elements.

Intellectual property

Patent currently being drafted related to know-how.

BADZAK

A real-time communication application supporting mobility based on SDN technology and Fog Computing. This innovation brings the Cloud closer to the end-user. It optimizes communication time by making the least possible use of distant networks (e.g.: 3G/3G+/4G cell phones). It also makes it possible to create a collaborative and participative community of users (drivers, pedestrians, cyclists, retailers, local community) in a defined area of interest.

Applications
Wide range of applications: local communities, car-sharing, traffic information, parking, events, extension of Campus network via vehicular relays, vehicle fleet management, etc.

Type of maturation
Maturation up to TRL6.

Stage of development
Performance of a POC on the UPEM site. Technology ready for transfer.

Intellectual property
Patentability approved in March 2018.

BeFC

Biofuel cell for practical and sustainable energy production that minimizes environmental impact. JETCELL technology exploits enzymes, carbon electrodes and micro-fluid applied to paper material.

Applications

This approach will not only allow the replacement of button cells for existing disposable or single-use applications, but also opens up new opportunities for low-power, ultra-thin health monitoring and Internet of Things (IoT) applications.

Type of maturation

Pre-maturation CARNOT POLYNAT followed by technical and economic maturation at LINKSIUM together with incubation support with a view to start-up creation.

Stage of development

A range of devices has been developed for the requirements of target markets and to meet the needs of feasibility studies under way with major industrial partners.

Intellectual property

The project is covered by six types of patents.

#FIVE et #SEVEN

#FIVE et #SEVEN proposes a graphical editor that simplifies the realization of scenarios and the creation of controllers/effectors, enabling simple supervision of the immersive experience. These technological advances make the creation of applications more accessible and deliver unparalleled productivity gains for designers/developers. This project was funded with support from the European Regional Development Fund (ERDF) for the Brittany Region.

Applications

The goal is to deliver a new generation of intuitive ergonomic tools, making it possible to design virtual and augmented reality applications without being an IT expert.

Type of maturation

Funding of the recruitment of three development and integration engineers, structuring of the marketing approach (MVP, Go To Market, test at leading trade fairs).

Stage of development

All the software solutions, of level TRL7, are packaged for Unity and accompanied by documentation as well as a tutorial. Training is also offered.

Intellectual property

Filing software with the APP. Creation and filing of the brand.

Luminous blue

The reproduction of atmospheric blue using a unique bitumen-based drawing technique. An experimental discovery made by an artist and subsequently developed through scientific collaborations; an innovative drawing technique produced a physical blue colour on paper. Extremely luminous, characterized and quantified by spectroscopy, it is similar to the blue of the atmosphere.

Applications
The most congruous markets for this innovation are contemporary art and the luxury sector.

Type of maturation
Technical and economic maturation with intellectual property management and a reglamentary study.

Stage of development
The blue is stable over time. The encapsulation of the colour in various media (jewellery, lighting, etc.) is in progress.

Intellectual property
Patent.

Transparent matrix

Transparent collagen matrix used as a graft substitute in corneal transplants. The research team has developed a transparent collagen-based matrix production process that does not require the addition of a crosslinking agent, which drastically reduces secondary effects (inflammation, risk of rejection, etc.).



Applications

The technology finds application in the field of ophthalmology and specifically in the replacement of defective or pathologic corneas (keratoconus, chemical burns, etc.).

Type of maturation

Technological maturation.

Stage of development

The results have made it possible to optimize the matrices and demonstrate their biocompatibility.

Intellectual property

Patent filed.

TALKROBOTS

Middleware for communication and interoperability of heterogeneous robots and smart connected devices, allowing easy integration with existing systems, resilience to failures, connected sensors integration (RFID, UWB, pressure, etc.), as well as distributed secured communications.

Applications

Industrial robotics applications:

- Integrator or end user: businesses needing to manage and optimize their robot fleet;
- Robotized assembly chain engineering, design and maintenance offices.

Service robotics applications:

- Industrial cleaning;
- Healthcare.

Type of maturation

Technological maturation (heterogeneous robot interoperability proof of concept, etc.). Patent filing.

Stage of development

POC - Configuration of a scenario implementing a fleet of heterogeneous robots, resilient to failure.

Intellectual property

Priority patent application filed with No. 18 51429 – 22/12/2018.

GLISS

GLISS, surface chemistry for early disease diagnosis, makes it possible to move away from non-specific interactions and increase biosensor sensitivity for all types of biomolecules: detection of a specific molecule even in a very small amounts of bodily fluids.

Applications

GLISS chemistry is applicable to even or uneven surfaces and has already proven itself with SPRi but can be used for any type of biochips, which today are prevalent in diagnosis.

Type of maturation

Maturation over 18 months at the LBPA: ENS Paris-Saclay/CNRS. €555 K investment.

Stage of development

A start-up led by Mme. Claude Nogues, will support the biochip diagnosis stakeholders.

Intellectual property

Two patents filed in 2019: applications to flat surfaces and nano-particles.

SATT PARIS-SACLAY
L'innovation en confiance

3D Laser Printing

3D printing by laser photopolymerization of resins. Unlike current procedures, this breakthrough innovation makes it possible to focus a laser beam, in the volume of the resin, and sculpt the material into a three-dimensional object unsupported and with time savings of a factor of 3 to 4.



Applications

The technique is suitable for the production of pieces using polymers available on conventional 3D printing markets, as well as pieces in glass or transparent silica for the jewellery, perfume and medical sectors, among others.

Type of maturation

Twelve-month maturation programme

Stage of development

Proof of concept consolidation.

Intellectual property

Patent Aix-Marseille Université, CNRS, Ecole Centrale Marseille.

SATT SUD-EST
ACCELERATING TECHNOLOGY TRANSFER

SON

SON proposes to immobilize the homogeneous chemical catalysts used in industrial processes on a new magnetic support by developing a nanotechnology (nano-platforms) that combine the advantages of homogeneous and heterogeneous catalysis: high activity, recoverable, reusable and therefore cheaper.

© Pixabay

Applications

The project aims to establish the SON start-up, whose main activity will be to offer magnetic nano-platform turnkey solutions with their specific catalyst and a magnetic recovery system. The target sector concerns synthesis for third parties (CDMO).

Type of maturation

Co-maturation with a company with a view to use in fine chemistry.

Stage of development

Nano-platforms are more efficient and recoverable over a number of cycles. Industrial validation achieved.

Intellectual property

Patent application filed in November 2018.

SAYENS SATT
CATALYSEUR D'INNOVATIONS

ETTRINGITE

Use of an ettringite material in a low pressure, low temperature (<100°C) heat storage procedure and its recovery as required. This reversible system achieves 70% output and would make it possible to ensure storage over long periods of time or in short cycles.

© Deltalab

Applications

Industrial:

- Storage and reuse of low temperature heat;
- Heating of small control room type units.

Tertiary:

- Maintaining temperature;
- Maintaining comfort levels.

Increase in temperature of water circuits.

Type of maturation

Development of a semi-industrial prototype to target transfer via operating licence.

Stage of development

TRL 4: laboratory validation of the technology.

Intellectual property

Patent application filed in 2015.
Europe - USA extension.

Researchers' Testimonies

Eric Dumas de la Roque

In the context of my work, I had the idea of developing a ventilation mask for premature babies. It has the advantage of being simple, robust, movable and more leak-proof than current systems, as well as providing treatment that is more effective and minimally invasive, therefore guaranteeing optimum evolution for premature infants.

I have nothing but praise for the quality of the collaboration with Vygon, the medical device manufacturer and specialist in neonatology with which we have signed a license agreement, as well as the team from SATT Aquitaine, which did some wonderful work upstream, in particular on the evaluation of the technology and negotiation. Although there are still numerous challenges to be overcome, all of the indications are that this project will result in a good product.

Hospital Doctor at Bordeaux University Hospital

AQUITAINE SCIENCE TRANSFERT
Accélérateur d'innovations

Anne-Dominique Lajoix

Having been selected following an initial call for projects, I started the COMET project with SATT AxLR three years ago. This human tissue bank (https://cometbiobank.com) would never have seen the light of day without the support and very close collaboration offered by the SATT team on a daily basis. They provided us with skills we did not have, particularly regarding contracts and business relations. The loans granted to us were for over €400,000. Today the very original model produced with Montpellier University Hospital and optimized by the SATT is regarded with particular interest by other university hospitals with tissue banks. On the back of this success, we have undertaken a second project with the SATT on therapeutic molecule research.

Montpellier University Professor
UFR Pharmacie
Manager of the Laboratoire Biocommunication en Cardio-Métabolique

Philippe Lavalle

The project to develop a new surfacing system that is both antimicrobial and anti-inflammatory based on biopolymers began within the laboratory. SATT Conectus detected this project and saw its potential. Very quickly, Conectus put a maturation project in place with significant funding, and this made it possible to validate numerous aspects of the technology and evaluate its capacity for becoming a product suitable for industrial manufacture and marketing. The entire Conectus team supported us with huge professionalism and responsiveness throughout the development phases. A strong bond of trust developed between us, which probably contributed to the success of this project. A new company, Spartha Medical, will now see the light of day!

Director of Research Inserm
Biomatériaux et Bioingénierie Laboratory, UMR_S
1121, Inserm, Strasbourg University

CONECTUS
FOURNISSEUR OFFICIEL D'INNOVATIONS

Marc Robert

SATT Erganeo has been supporting our technological developments for over six years now. Whether in the form of support for maturation, patent filing or in relations with industrialists and now start-up creation projects, SATT's assistance was particularly effective as initially, my research team had no experience in industrial optimization. This unfailing support with a team available and always ready to listen has already enabled us to file seven patents and sign two R&D collaboration contracts with major French manufacturers.

Professor at Paris University
"Réactivité et catalyse par transfert d'électrons" (REACTE) Team Manager
at the Laboratoire d'Électrochimie Moléculaire (LEM), Paris 13è

Sohaib El-Outmani

I have wanted to become an entrepreneur since my time at engineering school. After my thesis conducted through a partnership involving Singapore and Grenoble, and thanks to financial support and assistance from SATT Linksium, I naturally wanted to breathe life into my ideas by creating a start-up.

Currently at the maturation stage, I can better understand the business and communication side, which is new for me. The technology developed at ENTROVIEW can be used to diagnose and characterize a rechargeable battery, using not only electrical but also thermal data, particularly via the measurement of the entropy of the batteries.

The prospects for ENTROVIEW are promising, given the rapid growth in the electric vehicle market: this technology will enable us to use batteries in a longer term and safer way.

Post-doctoral researcher / Gipsa-lab – ENTROVIEW Project Lead

Pierre Jannin

The SATT has a determining role in my research projects today, a role that was long awaited. It provided essential support to facilitate the transfer of my research work to industry. This includes the management of intellectual property, market studies, assistance with technological maturation to increase the technology readiness level (TRL) and management of contractual relations with the manufacturer. We have also succeeded over time in building a relationship of long-term trust, enabling us to build the medicine of the future together.

Director of Research at INSERM - MEDICIS Team, LTSI (UMR 1099)
Chairman of CARS 2019

Charles Dumontet

I have been working with PULSALYS for several years on oncology projects that have since become start-ups such as Mablink and Hephaistos Pharma. PULSALYS played an essential role in their success, in particular thanks to material and financial support that led to proof of concepts (POCs). It is clear that PULSALYS is an essential player for academic people like us as the SATT provides skills that we do not possess at the CRCL. For example, being the intermediary vis-à-vis manufacturers during negotiation phases is a determining factor for project development. PULSALYS is really the realization of the optimization of scientific projects with support throughout the project from patent filing up to start-up creation. I would certainly continue to work with PULSALYS in the future.

Team Leader - Centre de Recherche en Cancérologie de Lyon (CRCL)
Supervision: Claude Bernard University Lyon 1, Inserm, CNRS and Centre Léon Bérard

Laurent Bouteiller

SATT Lutech is always there to help us optimize our discoveries in the field of supramolecular chemistry. Over the five last years, it has enabled us to file four patents, by taking charge both of their drafting and the cost of filing. Its support during the patent maturation phases is essential, because it manages all of the aspects outside of laboratory skills: putting us in contact with potential industrial partners, legal matters, eco-toxicological evaluation and the production costs of our products. SATT Lutech also negotiated the granting of a licence for us. Its knowledge of the market was decisive for meticulous evaluation of financial issues.

Institut Parisien de Chimie Moléculaire,
Sorbonne University

Michaël Baudoin

SATT Nord supported us with our project, its responsiveness enabled us to reconcile effective protection of the technology with the publication of our scientific results in an extremely competitive environment at international level. In order to hope to be able to set up a start-up on the basis of this technology and raise funds, we still needed to continue our work on the technology to make it marketable. SATT Nord supported us during this maturation phase and provided us with the financial and human resources to develop a demonstrator. So the SATT is an essential pillar for optimizing the value of research.

Professor at the Institut d'électronique de microélectronique et de nanotechnologie (IEMN – UMR 8520)

Bruno Figadere

Following the provision of services by SATT Paris-Saclay to the laboratory BioCIS, we can say that the outcome is extremely positive. In fact, no fewer than 12 projects have been identified as optimizable and a short report covering the context, impact of our results and additional data has been drafted for each project.
The action to be taken in the short or long term were identified for each of them.
Concerning teams working in more fundamental areas, the SATT experts made us aware of the importance of industrial protection, as well as the possibility of presenting ourselves as a candidate for a SATT call for projects in order to receive funding and support with a view to a partnership with a pharmaceutical manufacturer.

Director of UMR BioCIS
(Biomolecules: Design, Isolation Synthesis)

SATT PARIS-SACLAY
L'innovation en confiance

Laurent Vigouroux

The Smart Board provides climbers with quantified information on their physiological profile, fitness, qualities and weaknesses, enabling them to make progress on a scientific and individualised basis. Supported by SATT Sud-Est, the Smart Board is without doubt the first connected climbing innovation that integrates algorithms and scientific knowledge. And France is the first nation to equip itself with a training tool that is essential for our athletes' performance if they are to contend for medals in the Olympic Games.

Théo RAVANELLO and Dr. Laurent Vigouroux © 2019 Clément Lechaptois for SATT PACA Corse SAS

Inventor and Lecturer at Aix-Marseille Université, Institut des Sciences du Mouvement Etienne-Jules Marey (UMR 7287)

SATT SUD-EST
ACCELERATING TECHNOLOGY TRANSFER

Michel Paindavoine

With this testimony I would like to express my entire satisfaction on the subject of our collaboration with SAYENS and all of its people. Indeed, my team and I are particularly grateful for their professional and human skills, which reflect their sound scientific and technical knowledge in the area of artificial intelligence concerned, one of the main areas of our research. Similarly, through various common work meetings and presentations with customers or potential partners, I much appreciated interpersonal skills, as well as their aptitude in business relations. This was particularly the case recently during support for a major project with EDF.

Professor at the University of Burgundy
ESIREM & LEAD CNRS UMR 5022

SAYENS SATT
CATALYSEUR D'INNOVATIONS

Marie-Véronique Lelann


© TTT

P3S, Machine Learning software, is the result of work started in the late 70s by my colleague, José Aguilar-Martin, before AI became "fashionable". Since I joined the DISCO team in the late 90s, with the help of other researchers particularly including Tatiana Kempowsky-Hamon and Lyamine Hedjazi, we made improvements to it to address problems in areas as varied as the diagnosis of precision agriculture procedures and cancer diagnosis. Thanks to Toulouse Tech Transfer, it was possible to produce a tool that is transferable to businesses. As a researcher, it is particularly intellectually gratifying to see his work used in different areas, especially medicine.

Professor in the Department of Electrical Engineering and IT of INSA Toulouse, and Researcher at LAAS-CNRS with the DISCO (Diagnosis, Supervision and Behaviour) team.

TOULOUSE TECH TRANSFER

Company Testimonies

Olivier Guerret

We have designed a solution to replace insecticides using pheromones to combat the well known pest, the European grapevine moth, Lobesia botrana. We had already developed an original means of synthesis internally, but through our collaboration with SATT Aquitaine, we have been able to improve it and reach unrivalled levels of purity. We industrialised this process and have set up a production capacity in the region of 2T/week.

Our product is manufactured in France and we are awaiting European recognition in order to market it on the rest of the continent. A patent and license agreement were quickly put in place in a spirit of collaboration.

We entered into the partnership in order to have a flow of ideas shared with M. Pucheault's research team. And the result obtained was not as initially expected, it was even better! It is a wonderful story, so much so that we have reoriented the partnership to address other areas.

President of M2i Biocontrol

Patrice Luthi

MedXCell is a Swiss pharmaceutical group working in the area of cell therapy. The objectives of the MedXCell group consist of investing in R&D programmes in cell therapy, as well as producing and marketing cell therapy doses.

Created in 2018, in collaboration with CHU de Montpellier (University Hospital), MedXCell Science SAS is the subsidiary of the group specialising in R&D. MedXCell Science premises include research laboratories, a clean room and privileged access to numerous technical platforms of the IRMB (Institut de Médecine Régénératrice et de Biothérapie), and Montpellier University Hospital (CHU).

This enabled us to enter into an operating license agreement with SATT AxLR. As regards our development, patent filing, its value optimization and technology transfer were carried out very professionally by the AxLR teams.

Chief Executive Officer MedXCell Science SAS

Markus L.E. Ewert

Professor Baumert's project (INSERM UNISTRA, virus-patient interactions and liver disorders) was of remarkably high scientific quality.

The CONECTUS team provided a pertinent market perspective, which confirmed the full potential of the emerging technology. The combined involvement of CONECTUS and the IHU (Institut Hospitalo-Universitaire) enabled us to take valuable scientific knowledge into a commercial environment to develop medicines that patients suffering from liver disease urgently need.

PDG, ALENTIS

CONECTUS
FOURNISSEUR OFFICIEL D'INNOVATIONS

Bernard Dauvergne

ADDMEDICA is an independent French company that is geared to the development and provision of medical products for rare diseases, unmet medical needs and serious clinical situations.

Our collaboration with SATT Erganeo have always been extremely fruitful. First, because our contacts are able to propose cases that match our developmental pathways and, second, because they always make it possible for us to meet renowned researchers from diverse backgrounds such as the AP-HP or Inserm. An on-going and fruitful collaboration.

Co-founder ADDMEDICA

Yun Luo

Today, our team is taking major steps towards realizing our goal of becoming a world leader in circular economy.

ROSI's innovations have their sights on a circular economy for the photovoltaic (PV) industry by recycling waste from it, either from the slicing of PV wafers or from end-of-life PV modules. The main challenges are combining innovative technologies with industrial expertise and the interaction of a DeepTech start-up with large groups that define the ecosystem.

Linksium's assistance was a determining factor in structuring our team around our economic model. Tailored coaching continually obliged us to hone our strategy, structure our actions and remain focused on our priorities, which had to be continuously adapted in an evolving environment.

CEO ROSI SOLAR

François Decourcelle

Enovacom is a software publisher in the healthcare sector. It manages the journey patients' data takes up to its provision for various uses such as research, treatment and therapies. This technology is used in six university hospitals in western France and two cancer treatment centres. It is very demonstrative and many countries have expressed an interest in it.

Ouest Valorisation's contribution to this project was considerable: we had already worked with the researchers at the origin of the technology, but the SATT provided all the engineering that made it possible to move from prototype to the marketed product. Beyond technology transfer, the collaboration was strengthened by the setting up of a common laboratory.

Product Marketing Manager, Enovacom

OUEST VALORISATION
Ressources d'innovation

Didier Neuzeret

ViewPoint specializes in the analysis of laboratory animal behaviour.

The first to have automated rodent locomotion tracking by image analysis. The technology transferred by PULSALYS is the fruit of the collaboration between the CRNL and INL laboratories, which made it possible to produce a miniature wireless device for multi-parameter measurement that provides supplementary physiological information. The researchers from the laboratories we already knew contacted PULSALYS with a view to making this transfer of technologies possible. PULSALYS formalized the asset, protected it and acted as single point of contact, enabling ViewPoiont to market the product in the shortest possible time.

CEO of ViewPoint

PULSALYS

Olivier Detournay

Planktovie approached SATT Lutech in 2018, with a view to acquiring the exclusive rights to a patent developed in the Jean Perrin laboratory (SU-CNRS) and the Institut de Biologie Paris-Seine. It concerns an innovative distributor of nutritional solutions for fish, which operates by vibration. A deal was rapidly finalized enabling Planktovie to market its first product, a dry feed dispenser, the Fishgun D1. Thanks to its proximity to the aquaculture market and nutritional solutions for fish, as well as its technical knowledge,

Planktovie was able to validate and improve the invention to better meet its customers' requirements. A variation for dispensing planktonic type liquid nutrition is currently being finalized.

CEO of Planktovie

Nicolas El Robrini

The numerous years of research devoted to the development of new types of molecules with an anti-AGE and anti-ALE effect, the renown of researchers from Amiens, as well as the power of an international patent and its potential applications in cosmetics and healthcare motivated me to contact SATT Nord. It was receptive and attentive to my wish to optimize this research work by creating a start-up to market these innovations. It agreed to demonstrate the non-toxicity of the molecules present in the patent, which make it possible to reduce the risk of the project before creating the company Pharm'Aging, thereby supporting me in the decision to sign an exclusive license agreement. The various project managers at SATT Nord listened to Pharm'Aging's needs to reach an agreement that would be satisfactory for both parties and enable the company to get off to a good start. So, SATT Nord is the first partner in the successful launch of Pharm'Aging.

Founding President of Pharm'Aging

Habib Al Khatib

A DeepTech start-up often comprises profiles that are more scientific than financial. Through their knowledge of both areas, the experts at the SATT were the perfect link, enabling us to ask the right questions at the right time: the start of our fundraising.

Thanks to our collaboration, we quickly succeeded in obtaining the French Tech Seed label, which helped us realize our ambition: making SpotLight the leader in the detection of subsurface change.

Founding President of SPOTLIGHT

SATT PARIS-SACLAY
L'innovation en confiance

Thibaud Sellam

© Nanoz

Nanoz is delighted to have developed products based on two gas sensor technologies originating in public research. OptoSensor, an atmospheric pollutant and ethanol sensor with an unrivalled cost-performance ratio that is designed to detect gas in wet environments and capable of achieving the performance of top-of-the-range sensors. And Generic Transducer, the basis for a new generation of MOS technology, making Nanoz sensors the only ones to be selective, the most sensitive and reliable, the least energy-consuming, among the smallest in the World and the cheapest to manufacture. Co-developments by M2NP (Aix-Marseille Université CNRS) and supported by SATT Sud-Est give the technology credibility thanks to the international aura of its co-inventors, who include Prof. Khalifa Aguir. Nanoz solutions will enable connected objects to produce applications that do not exist today.

President of Nanoz

SATT SUD-EST
ACCELERATING TECHNOLOGY TRANSFER

Alexis Roche

Cooperation with SATT SAYENS provides an opportunity to forge links with universities and, in particular, with the UTT (Université de technologie de Troyes). It is also an excellent means of bringing the university and the business worlds together, as well as a way of optimizing the value of research originating in laboratories and transforming it into marketable products.

President - General Manager of ASSYSTEL

SAYENS SATT
CATALYSEUR D'INNOVATIONS

Franck Gallardo


© NeoVirTech

NeoVirTech develops auto-fluorescent viruses for the imagery and research of new antiviral drugs. A spin-off of the CNRS created in 2014, the company obtained the exclusive license for ANCH0R technology, used to detect DNA in real time in living cells by microscopy. This licence successfully concluded an 18-month maturation programme financed by TTT. The company develops fluorescent viral models for the human, veterinary and bio-defence markets.

The winner of the ILab award from the Ministry for Research and Further Education in the emerging category in 2013, and the creation-development category in 2016, NeoVirTech quickly became a major player in antiviral screening, being ranked by the magazine Pharma Tech Outlook among the Top10 drug discovery companies. Europe 2019.

CEO NeoVirTech SAS

SATT
Réseau
Les Sociétés d'Accélération du Transfert de Technologies

Association des SATT Non-profit association
under French law of 1st July 1901.
Headquarters : c/o Erganeo | 37 rue de Lyon,
75012 Paris | **www.satt.fr**